Fig. 7: Most frequently applied third-line treatment regimens in multiple myeloma patients, initiation of third-line treatment 2004–2021.
From: Second- and third-line treatment strategies in multiple myeloma: a referral-center experience
CYBORD cyclophosphamide-bortezomib-dexamethasone, D dexamethasone, Dara daratumumab, I ixazomib, K carfilzomib, MP melphalan-prednisone, P pomalidomide, R lenalidomide, T thalidomide, V bortezomib, VDT-PACE bortezomib, dexamethasone, thalidomide, cisplatin, doxorubicin, cyclophosphamide, and etoposide.
